A small cyclic peptide derived from viper venom reduced MS-like disease in mice as effectively as current antibody treatments, with no immune reactions or toxic side effects.
8-amino-acid peptidevenom-derived cyclic peptide matched antibody therapy's mechanism for MS with no immunogenicity and no off-target effects in mice
What the researchers found
Visabron c(4-4), a backbone cyclic octapeptide derived from viper venom disintegrin, effectively reduced EAE disease severity in mice while showing no immunogenicity or off-target toxicity.
Why it matters
Natalizumab works well for MS but carries the risk of a serious brain infection (PML) with long-term use. A small peptide that does the same job without triggering immune reactions could be a safer alternative.
The numbers in context
8-amino-acid cyclic peptide; dual alpha4beta1/alpha9beta1 antagonist; no immunogenicity; no off-target effects
How the study worked
Peptide design and synthesis from a minilibrary with conformational diversity. Functional adhesion cellular assays for potency/selectivity. Serum stability and pharmacokinetics testing. In vivo efficacy in EAE mouse model (IP injection). Safety assessed via blood analysis, tissue pathology, immunogenicity, and off-target effects.
Who was studied
Mice with experimental autoimmune encephalomyelitis (EAE)
What this study cannot tell us
Animal study only (mice with EAE, not humans with MS). EAE does not perfectly mirror human MS. Specific dosing and duration details limited. No head-to-head comparison with natalizumab in the same model. Long-term safety in animals not reported.
How to read the evidence
Preclinical study with comprehensive characterization: in vitro selectivity assays, pharmacokinetics, in vivo efficacy in EAE mouse model, and extensive safety testing. Published in JACS Au (ACS journal). However, it remains animal data without human validation, and EAE doesn't perfectly model human MS.
When this study was published
Published in 2021 in JACS Au. The backbone cyclic peptide approach and venom-derived design represent active areas of peptide drug development.
The bigger picture
Replacing monoclonal antibodies with small peptide mimetics is a major trend in pharmaceutical development. Visabron demonstrates that venom-derived peptides — shaped by evolution to interact precisely with integrins — can be re-engineered as safe, non-immunogenic drugs. Success in MS could open the door for similar approaches in Crohn's disease, ulcerative colitis, and other autoimmune conditions where α4 integrins play a role.
Questions still open
- Would visabron show efficacy in human MS clinical trials, given the limitations of the EAE mouse model?
- Could oral formulation of this cyclic peptide be achieved, or is injection required?
- How does visabron's integrin-blocking potency compare head-to-head with natalizumab in the same experimental system?
Common questions
Why is a small peptide potentially safer than the antibody natalizumab?
How was viper venom used to design this drug?
Read the original research
Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.
JACS Au, 1(12), 2361-2376
Citation
Gilon, Chaim; Klazas, Michal; Lahiani, Adi; Schumacher-Klinger, Adi; Merzbach, Shira; Naoum, Johnny N; Ovadia, Haim; Rubin, Limor; Cornell-Kennon, Susan; Schaefer, Erik M; Katzhendler, Jehoshua; Marcinkiewicz, Cezary; Hoffman, Amnon; Lazarovici, Philip. (2021). Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.. JACS Au, 1(12), 2361-2376. https://doi.org/10.1021/jacsau.1c00496